Neoadjuvant Systemic Therapy for Breast Cancer

  • Ana M. Gonzalez-Angulo
  • Gabriel N. Hortobagyi


Neoadjuvant systemic therapy is defined as the first systemic treatment a patient receives after cancer is diagnosed, and the term indicates that subsequent therapies are intended. Other terms used in clinical practice that involve this concept are preoperative, induction, or primary systemic therapy. This chapter provides an overview of the general benefits of and common regimens used as neoadjuvant therapy in breast cancer


Sentinel Lymph Node Sentinel Lymph Node Biopsy Inflammatory Breast Cancer Hormone Receptor Status Operable Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.PubMedGoogle Scholar
  3. 3.
    Mauriac L, Durand M, Chauvergne J, Dilhuydy JM, Bonichon F. Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen. Ann Oncol. 1992;3:439–43.PubMedGoogle Scholar
  4. 4.
    Buzdar AU, Hortobagyi GN, Asmar L, et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol. 1997;24:17–9.Google Scholar
  5. 5.
    Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Pouillart P, Fumoleau P, Romieu G, et al. Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide and doxorubicin/Taxol (paclitaxel) as neoadjuvant treatment of local-regional breast cancer. Proc Am Soc Clin Oncol. 1999;18:73a.Google Scholar
  7. 7.
    Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial [Erratum appears in J Clin Oncol. 2003;21:2048]. J Clin Oncol. 2003;21:968–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17:3412–7.PubMedGoogle Scholar
  9. 9.
    Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol. 2001;20:129.Google Scholar
  10. 10.
    Evans TRJ, Gould A, Foster E, Crown JP, Leonard RCF, Mansi JL. Phase III randomised trial of adriamycin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer: an ACCOG study. Proc Am Soc Clin Oncol. 2002;21:136a.Google Scholar
  11. 2010.
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol. 2003;86:295–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Buzdar AU, Ibrahim N, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.PubMedGoogle Scholar
  17. 17.
    Rahman Z, Buzdar AU, Singletary E, Hortobagyi GN. Selection of systemic therapy: is axillary lymph node status important? Sem Breast Dis. 1998;1:157–66.Google Scholar
  18. 18.
    Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997;3:1565–9.PubMedGoogle Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  • Ana M. Gonzalez-Angulo
    • 1
  • Gabriel N. Hortobagyi
  1. 1.Department of Breast Medical Oncology and Systems BiologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations